Sector ETFs — End-of-Day Verdict
1 ACQUIRE, 0 DISPOSE, 1 QUEUE WITHDRAWN. IBB -- BUY AT MARKET @,, stop, execute at the 2026-07-31 open. The FOMC sell-off was erased in one session by the largest single-day market-cap gain ever recorded (Microsoft +15.5%, Azure past $100bn), Nasdaq +2.78% and SMH +6.88% -- and every name that led prints NO TRADE cv0 while all three actionable BUYs were the day's laggards. IBB is taken because it is the first candidate in five weeks to pass the arithmetic gate the book has declined everything on: its own 4-week estimate (+2.98%) exceeds its stop distance (2.22%), its stop is properly sized at 1.21 ATR rather than the sub-ATR stops that make this family's 0.667 stop-first rate self-fulfilling, it closed BELOW its anchored VWAP so the at-market entry is not a chase, and it built over four sessions off WATCH rather than spiking. It is still the -3 FailedBreakdown family and it still underperformed a +1.66% tape, which is why it takes the standing unit and works the 4-week objective, not the 12-week. SKYY carries the book's highest adjusted conviction (75) and is declined anyway -- a 0.58 ATR stop on a 0.667-stop-first family, a 4-week estimate (+0.61%) smaller than the distance to that stop, and decisively a cloud ETF that managed +1.06% on the day Azure crossed $100bn. XLF fails the floor at 63 with all three forward tenors below its own entry. The 07-29 XLE limit is withdrawn unfilled -- the price never came within 1.9% of it and conviction went. -> 24.7%, preserved.
Recommendations
1 to acquire · 0 to dispose
| Ticker | Name | Close | Action | Action Price Where to act — a buy-limit on a pullback or a buy-stop above resistance, not the current price. Sanity-check vs Close: on a held name, an action price stranded above the close means the queued level was set when the stock was higher — stale, awaiting reprice. | Stop The risk-defined exit, set below the entry for a long (~1.2–1.8×ATR). A held long whose Stop sits at/above the Close is already below its stop — a stale box awaiting reprice. | 1wk Model estimate of the likely price at this horizon — a forward projection, not a guarantee, and separate from the trade's Action Price or Stop. Where the ML estimator is enabled these are per-ticker calibrated forecasts (~80% coverage band) that are refreshed periodically and can drift between refreshes; otherwise they're interpolated from the signal's swing target. Confirm against the settled close. | 4wk Model estimate of the likely price at this horizon — a forward projection, not a guarantee, and separate from the trade's Action Price or Stop. Where the ML estimator is enabled these are per-ticker calibrated forecasts (~80% coverage band) that are refreshed periodically and can drift between refreshes; otherwise they're interpolated from the signal's swing target. Confirm against the settled close. | 12wk Model estimate of the likely price at this horizon — a forward projection, not a guarantee, and separate from the trade's Action Price or Stop. Where the ML estimator is enabled these are per-ticker calibrated forecasts (~80% coverage band) that are refreshed periodically and can drift between refreshes; otherwise they're interpolated from the signal's swing target. Confirm against the settled close. | Rationale |
|---|---|---|---|---|---|---|---|---|---|
| IBB | iShares Biotechnology ETF | 189.96 | BUY | 189.96 | 185.75 | 190.60 (+0.3%) | 195.62 (+3.0%) | 199.94 (+5.3%) | Buying biotechnology into a confirmed sector uptrend at a price that is not chasing it. Biotech has been one of the market's strongest groups -- IBB is up roughly 51% over the past year on a wave of takeovers as a friendlier regulatory backdrop brought cash-rich drugmakers back as buyers -- and the fund has now broken decisively above the level it spent months failing at. Thursday's close of is a pullback within that breakout, 4.6% below the twelve-month high and, importantly, slightly BELOW the fund's own volume-weighted average price, so this buys a dip rather than a top tick. The day itself was the tell: broad healthcare fell 1.64% and IBB's own holding Alnylam collapsed about 25% to a one-year low on a guidance cut, yet the fund still closed higher and the equal-weight biotech index rose 2.4% -- the sector absorbed a blow-up in a member and kept going. The trade is sized to lose little and honours a stop at. Main risk, stated plainly: biotech is one of the most rate-sensitive corners of the market and the 30-year Treasury yield just hit a multi-decade high near 5.24%, the one thing that did not recover when equities rebounded. OPERATIONAL: only candidate whose Est_4W (+2.98%) EXCEEDS its stop distance (2.22%) -- the standing gate that declined XLP 07-27, SKYY 07-29, XLF/XLI/XLV 07-24. Stop is 1.21 ATR (vs SKYY's 0.58 ATR) at the session low 185.75 -- properly sized, does not manufacture the family's 0.667 stop-first rate. 4-session build W57->W57->W59->B75, no cv0 spike. SE-1: this IS the -3 FailedBreakdown_Up_20D family, taken only because it clears the 65 floor AFTER the live haircut. SE-2: horizons monotonic/non-inverted (+0.34/+2.98/+5.25%) so SE-2 does not formally bite, BUT the family is 0-for-9 on 4wk targets on this book, so carry as a <=4-week TACTICAL SWING on the stop, not a position hold; work the +2.98% 4wk objective, not the 12wk. L5/SE-3: 1wk low-reliability (calib_1w -0.08). ADV-1: at-market is the only structure available (Order_Type Market, Entry_Price==Close); acceptable only because the close is 0.8% BELOW the anchored VWAP 191.49 and RSI is 56. L8: executes at the 2026-07-31 open -- June PCE AND the month-end index rebalance both land on that session, so a >1.5% gap is materially more likely than usual; reprice/re-validate if so. Sized to the book convention of 25% of declared, not the raw 49.24% portion formula. ADR-0019 human book: record TAKEN or SKIPPED next run. · news |
| _PORTFOLIO | Sector ETFs | — | WATCH | — | — | n/a | n/a | n/a | 1 ACQUIRE, 0 DISPOSE, 1 QUEUE WITHDRAWN. Thursday erased the Fed sell-off in a single session on the largest one-day market-cap gain ever recorded -- Microsoft +15.5% with Azure past $100bn -- lifting the Nasdaq 2.78% and semiconductors 6.88%. The book's response is deliberately unglamorous: every name that led the rally carries no trading signal at all, and the three that do signal were the day's laggards. We are buying one of them -- the biotechnology fund -- because it is the only candidate whose own four-week price view is larger than the distance to its protective stop, because that stop is properly sized rather than sitting inside a single day's noise, and because it closed below its own average price, so the entry is a dip rather than a chase. Biotech is separately in a confirmed uptrend on a takeover wave, and it closed higher on a day broad healthcare fell 1.64% and one of its own holdings dropped 25%. We passed on the cloud fund despite it scoring highest: a cloud vehicle that gains 1% on the biggest cloud earnings print of the year, with a stop barely a day's range away, is not a trade. Financials were passed for the third session -- every one of the model's forward estimates sits below today's price. The energy limit placed on Wednesday is cancelled unfilled; the price never came within 1.9% of it and the signal died anyway. OPERATIONAL: IBB at-market @189.96,, stop 185.75, execute 2026-07-31 open (PCE + month-end rebalance land on that session -- gap risk elevated). -> 24.7%, preserved. ANTICIPATE slot: none eligible (zero ANTICIPATE prints on the anchor; AnticipationUp_VCP bias -10, 0-for-5). DISPOSE: none -- flat book, no holdings, no stop breaches. Valuation blind (all-ETF NA_ETF, FetchedAt 2026-06-11, regen skipped per Step 3). calib_1w -0.08 degenerate (SE-3). Overlay 07-05 is 26d stale -- refresh overdue. · news |
Outcome & track record
Accuracy at the time of this record.
27 Graded decisions Past recommendations old enough to score against what actually happened (target hit / stopped out / closed). This is the evidence base — the bigger the number, the more history behind the calls. Click to inspect every one. See the decisions →
-0.080 1-week calibration How much of the eventual 4-week move typically shows up in the first week (0 = almost none, 1 = most of it). Use it to read the 1-week estimates: a low number means prices drift toward the target slowly, so don't over-read a soft week-1.
21 Published records How many dated end-of-day verdicts exist for this book — the length of the public track record you can browse in the Archive below.